|
1
|
Gottlieb JA, Benjamin RS, Baker LH, et al:
Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer
Treat Rep. 60:199–203. 1976.PubMed/NCBI
|
|
2
|
Stevens MF, Hickman JA, Langdon SP, et al:
Antitumor activity and pharmacokinetics in mice of
8-carbamoyl-3-methyl-imidazo [5,1-d]-1,2,3,5-tetrazin-4(3H)-one
(CCRG 81045; M & B 39831), a novel drug with potential as an
alternative to dacarbazine. Cancer Res. 47:5846–5852.
1987.PubMed/NCBI
|
|
3
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
MoreiraGonzalez A, Djohan R and Lohman R:
Considerations surrounding reconstruction after resection of
musculoskeletal sarcomas. Cleve Clin J Med. 77 (Suppl 1):S18–S22.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Trent JC, Beach J, Burgess MA, et al: A
two-arm phase II study of temozolomide in patients with advanced
gastrointestinal stromal tumors and other soft tissue sarcomas.
Cancer. 98:2693–2699. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Garcia del Muro X, Lopez-Pousa A, Martin
J, Buesa JM, Martinez-Trufero J, Casado A, Poveda A, Cruz J, Bover
I and Maurel J: Spanish Group for Research on Sarcomas: A phase II
trial of temozolomide as a 6-week, continuous, oral schedule in
patients with advanced soft tissue sarcoma: A study by the Spanish
Group for Research on Sarcomas. Cancer. 104:1706–1712. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stacchiotti S, Tortoreto M, Bozzi F, et
al: Dacarbazine in solitary fibrous tumor: A case series analysis
and preclinical evidence vis-a-vis temozolomide and
antiangiogenics. Clin Cancer Res. 19:5192–5201. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Casey DA, Wexler LH, Merchant MS, Chou AJ,
Merola PR, Price AP and Meyers PA: Irinotecan and temozolomide for
Ewing sarcoma: The Memorial Sloan-Kettering experience. Pediatr
Blood Cancer. 53:1029–1034. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Raciborska A, Bilska K, Drabko K, Chaber
R, Pogorzala M, Wyrobek E, Polczyńska K, Rogowska E,
RodriguezGalindo C and Wozniak W: Vincristine, irinotecan and
temozolomide in patients with relapsed and refractory Ewing
sarcoma. Pediatr Blood Cancer. 60:1621–1625. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hotta T, Motoyama T and Watanabe H: Three
human osteosarcoma cell lines exhibiting different phenotypic
expressions. Acta Pathol Jpn. 42:595–603. 1992.PubMed/NCBI
|
|
11
|
Imaizumi S, Motoyama T, Ogose A, Hotta T
and Takahashi HE: Characterization and chemosensitivity of two
human malignant peripheral nerve sheath tumour cell lines derived
from a patient with neurofibromatosis type 1. Virchows Arch.
433:435–441. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hoshino M, Kawashima H, Ogose A, et al:
Serum CA 125 expression as a tumor marker for diagnosis and
monitoring the clinical course of epithelioid sarcoma. J Cancer Res
Clin Oncol. 136:457–464. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sonobe H, Manabe Y, Furihata M, Iwata J,
Oka T, Ohtsuki Y, Mizobuchi H, Yamamoto H, Kumano O and Abe S:
Establishment and characterization of a new human synovial sarcoma
cell line, HS-SY-II. Lab Invest. 67:498–505. 1992.PubMed/NCBI
|
|
14
|
Kawai A, Naito N, Yoshida A, et al:
Establishment and characterization of a biphasic synovial sarcoma
cell line, SYO-1. Cancer Lett. 204:105–113. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Aman P, Ron D, Mandahl N, et al:
Rearrangement of the transcription factor gene CHOP in myxoid
liposarcomas with t(12;16)(q13;p11). Genes Chromosomes Cancer.
5:278–285. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hoshino M, Ogose A, Kawashima H, et al:
Molecular analyses of cell origin and detection of circulating
tumor cells in the peripheral blood in alveolar soft part sarcoma.
Cancer Genet Cytogenet. 190:75–80. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kusakabe H, Iwasaki H, Sano K and Kiyokane
K: Expression of lung resistance protein in epithelioid sarcoma in
vitro and in vivo. Arch Dermatol Res. 292:292–300. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
FernandesAlnemri T, Litwack G and Alnemri
ES: CPP32, a novel human apoptotic protein with homology to
Caenorhabditis elegans cell death protein Ced-3 and mammalian
interleukin-1 beta-converting enzyme. J Biol Chem. 269:30761–30764.
1994.PubMed/NCBI
|
|
19
|
Oliver FJ, de la Rubia G, Rolli V, et al:
Importance of poly (ADP-ribose) polymerase and its cleavage in
apoptosis. Lesson from an uncleavable mutant. J Biol Chem.
273:33533–33539. 1998.PubMed/NCBI
|
|
20
|
Liu H, Zhou L, Shi S, et al:
Oligosaccharide G19 inhibits U-87 MG human glioma cells growth in
vitro and in vivo by targeting epidermal growth factor (EGF) and
activating p53/p21 signaling. Glycobiology. 24:748–765. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wu L, Yang L, Xiong Y, et al: Annexin A5
promotes invasion and chemoresistance to temozolomide in
glioblastoma multiforme cells. Tumour Biol. 35:12327–12337. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 352:997–1003. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jakob J, Hille M, Sauer C, Ströbel P, Wenz
F and Hohenberger P: O6-methylguanine-DNA methyltransferase (MGMT)
promoter methylation is a rare event in soft tissue sarcoma. Radiat
Oncol. 7:1802012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
DeSalvo M, Maresca G, D'agnano I, et al:
Temozolomide induced c-Myc-mediated apoptosis via Akt signalling in
MGMT expressing glioblastoma cells. Int J Radiat Biol. 87:518–533.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang H, Cai S, Ernstberger A, Bailey BJ,
Wang MZ, Cai W, Goebel WS, Czader MB, Crean C, Suvannasankha A, et
al: Temozolomide-mediated DNA methylation in human myeloid
precursor cells: Differential involvement of intrinsic and
extrinsic apoptotic pathways. Clin Cancer Res. 19:2699–2709. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kanzawa T, Germano IM, Kondo Y, Ito H, Kyo
S and Kondo S: Inhibition of telomerase activity in malignant
glioma cells correlates with their sensitivity to temozolomide. Br
J Cancer. 89:922–929. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Roos WP, Batista LF, Naumann SC, Wick W,
Weller M, Menck CF and Kaina B: Apoptosis in malignant glioma cells
triggered by the temozolomide-induced DNA lesion
O6-methylguanine. Oncogene. 26:186–197. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hirose Y, Berger MS and Pieper RO: p53
effects both the duration of G2/M arrest and the fate of
temozolomide-treated human glioblastoma cells. Cancer Res.
61:1957–1963. 2001.PubMed/NCBI
|
|
29
|
Kanzawa T, Germano IM, Komata T, Ito H,
Kondo Y and Kondo S: Role of autophagy in temozolomide-induced
cytotoxicity for malignant glioma cells. Cell Death Differ.
11:448–457. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mahalingam D, Mita A, Sankhala K, Swords
R, Kelly K, Giles F and Mita MM: Targeting sarcomas: Novel
biological agents and future perspectives. Curr Drug Targets.
10:937–949. 2009. View Article : Google Scholar : PubMed/NCBI
|
